Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
British Journal of Cancer, Published online: 07 November 2023; doi:10.1038/s41416-023-02477-7Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy (Source: British Journal of Cancer)
Source: British Journal of Cancer - November 7, 2023 Category: Cancer & Oncology Authors: Luca Licata Marco Barreca Barbara Galbardi Matteo Dugo Giulia Viale Bal àzs Győrffy Thomas Karn Lajos Pusztai Luca Gianni Maurizio Callari Giampaolo Bianchini Source Type: research
Radiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis
British Journal of Cancer, Published online: 06 November 2023; doi:10.1038/s41416-023-02480-yRadiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis (Source: British Journal of Cancer)
Source: British Journal of Cancer - November 6, 2023 Category: Cancer & Oncology Authors: Benjamin Hunter Christos Argyros Marianna Inglese Kristofer Linton-Reid Ilaria Pulzato Andrew G. Nicholson Samuel V. Kemp Pallav L. Shah Philip L. Molyneaux Cillian McNamara Toby Burn Emily Guilhem Marcos Mestas Nu ñez Julia Hine Anika Choraria Prashanth Source Type: research
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer
British Journal of Cancer, Published online: 03 November 2023; doi:10.1038/s41416-023-02481-xCorrection: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer (Source: British Journal of Cancer)
Source: British Journal of Cancer - November 3, 2023 Category: Cancer & Oncology Authors: Masayuki Shirasawa Tatsuya Yoshida Kouya Shiraishi Naoko Goto Shigehiro Yagishita Tatsuya Imabayashi Yuji Matsumoto Ken Masuda Yuki Shinno Yusuke Okuma Yasushi Goto Hidehito Horinouchi Masaya Yotsukura Yukihiro Yoshida Kazuo Nakagawa Katsuhiko Naoki Takaa Source Type: research
Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption
British Journal of Cancer, Published online: 02 November 2023; doi:10.1038/s41416-023-02479-5Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption (Source: British Journal of Cancer)
Source: British Journal of Cancer - November 2, 2023 Category: Cancer & Oncology Authors: Shivani Bailey Marta Ferraresso Luz Alonso-Crisostomo Dawn Ward Stephen Smith James C. Nicholson Harpreet Saini Anton J. Enright Cinzia G. Scarpini Nicholas Coleman Matthew J. Murray Source Type: research
Targeting the COMMD4–H2B protein complex in lung cancer
British Journal of Cancer, Published online: 01 November 2023; doi:10.1038/s41416-023-02476-8Targeting the COMMD4–H2B protein complex in lung cancer (Source: British Journal of Cancer)
Source: British Journal of Cancer - November 1, 2023 Category: Cancer & Oncology Authors: Ming Tang Joshua T. Burgess Mark Fisher Didier Boucher Emma Bolderson Neha S. Gandhi Kenneth J. O ’Byrne Derek J. Richard Amila Suraweera Source Type: research
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
British Journal of Cancer, Published online: 01 November 2023; doi:10.1038/s41416-023-02413-9Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study (Source: British Journal of Cancer)
Source: British Journal of Cancer - November 1, 2023 Category: Cancer & Oncology Authors: Florence Duffaud Jean-Yves Blay Axel Le Cesne Christine Chevreau Pascaline Boudou-Rouquette Elsa Kalbacher Nicolas Penel Christophe Perrin Val érie Laurence Emmanuelle Bompas Esma Saada-Bouzid Corinne Delcambre Fran çois Bertucci Mathilde Cancel Camille Source Type: research
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
British Journal of Cancer, Published online: 30 October 2023; doi:10.1038/s41416-023-02474-wEfficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 30, 2023 Category: Cancer & Oncology Authors: Jung Hyun Jo Yong-Tae Kim Ho Soon Choi Ho Gak Kim Hong Sik Lee Young Woo Choi Dong Uk Kim Kwang Hyuck Lee Eui Joo Kim Joung-Ho Han Seung Ok Lee Chang-Hwan Park Eun Kwang Choi Jae Woo Kim Jae Yong Cho Woo Jin Lee Hyungsik Roger Moon Mi-Suk Park Sangjae Kim Source Type: research
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy
British Journal of Cancer, Published online: 28 October 2023; doi:10.1038/s41416-023-02472-yModifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 28, 2023 Category: Cancer & Oncology Authors: Xiaoshuang Feng Yiwen Zhang J. Bailey Vaselkiv Ruifeng Li Paul L. Nguyen Kathryn L. Penney Edward L. Giovannucci Lorelei A. Mucci Konrad H. Stopsack Source Type: research
Immune check points in cancer treatment: current challenges and perspectives
British Journal of Cancer, Published online: 28 October 2023; doi:10.1038/s41416-023-02478-6Immune check points in cancer treatment: current challenges and perspectives (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 28, 2023 Category: Cancer & Oncology Authors: Joseph Ciccolini Gerard Milano Source Type: research
Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma
British Journal of Cancer, Published online: 28 October 2023; doi:10.1038/s41416-023-02458-wTotal neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 28, 2023 Category: Cancer & Oncology Authors: Hollie A. Clements Tim J. Underwood Russell D. Petty Source Type: research
Associations of dietary patterns with kidney cancer risk, kidney cancer-specific mortality and all-cause mortality among postmenopausal women
British Journal of Cancer, Published online: 28 October 2023; doi:10.1038/s41416-023-02469-7Associations of dietary patterns with kidney cancer risk, kidney cancer-specific mortality and all-cause mortality among postmenopausal women (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 28, 2023 Category: Cancer & Oncology Authors: Qi Jin Jinesh Gheeya Sushma Nepal Ni Shi Edmund Folefac Maxine Z. Webb Elizabeth M. Grainger Lai Wei Jason M. Prosek Brian C. Focht Michael Gong Steven K. Clinton Fred K. Tabung Source Type: research
The Cyclin-dependent kinase 1: more than a cell cycle regulator
British Journal of Cancer, Published online: 28 October 2023; doi:10.1038/s41416-023-02468-8The Cyclin-dependent kinase 1: more than a cell cycle regulator (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 28, 2023 Category: Cancer & Oncology Authors: Giorgia Massacci Livia Perfetto Francesca Sacco Source Type: research
Body composition and cancer survival: a narrative review
British Journal of Cancer, Published online: 27 October 2023; doi:10.1038/s41416-023-02470-0Body composition and cancer survival: a narrative review (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 27, 2023 Category: Cancer & Oncology Authors: Patrick T. Bradshaw Source Type: research
The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma
British Journal of Cancer, Published online: 26 October 2023; doi:10.1038/s41416-023-02464-yThe novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Zhijian Kuang Kaiqiang Guo Yin Cao Mengxue Jiang Chaojie Wang Qiaoqiong Wu Guosheng Hu Mingtao Ao Mingfeng Huang Jingbo Qin Taige Zhao Sheng Lu Cuiling Sun Mingyu Li Tong Wu Wen Liu Meijuan Fang Source Type: research
Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges
British Journal of Cancer, Published online: 26 October 2023; doi:10.1038/s41416-023-02466-wSupporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges (Source: British Journal of Cancer)
Source: British Journal of Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Hannah R. Wardill Luke T. Wooley Olivia M. Bellas Katrina Cao Courtney B. Cross Madele van Dyk Ganessan Kichenadasse Joanne M. Bowen Andrew C. W. Zannettino Sepehr Shakib Gregory B. Crawford Jaroslav Boublik Mellar M. Davis Scott D. Smid Timothy J. Price Source Type: research
